Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.

Leroux-Roels G, Van Belle P, Vandepapeliere P, Horsmans Y, Janssens M, Carletti I, Garçon N, Wettendorff M, Van Mechelen M.

Vaccine. 2015 Feb 18;33(8):1084-91. doi: 10.1016/j.vaccine.2014.10.078. Epub 2014 Nov 7.

2.

Retraction of the letter: "Comment on 'CD4⁺ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy' ".

van der Most R, Wettendorff M, Innis B, Hanon E.

Sci Transl Med. 2014 Sep 24;6(255):255rt2. doi: 10.1126/scitranslmed.3010397. No abstract available.

PMID:
25253677
3.

Seeking help: B cells adapting to flu variability.

van der Most RG, Roman FP, Innis B, Hanon E, Vaughn DW, Gillard P, Walravens K, Wettendorff M.

Sci Transl Med. 2014 Jul 23;6(246):246ps8. doi: 10.1126/scitranslmed.3008409.

PMID:
25101885
4.
5.

Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.

van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E.

Hum Vaccin Immunother. 2014;10(3):572-6. Epub 2013 Dec 16.

6.

Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Schleiss MR, Choi KY, Anderson J, Mash JG, Wettendorff M, Mossman S, Van Damme M.

Vaccine. 2014 May 13;32(23):2756-62. doi: 10.1016/j.vaccine.2013.07.010. Epub 2013 Jul 16.

7.

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.

Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M.

BioDrugs. 2011 Aug 1;25(4):217-26. doi: 10.2165/11591760-000000000-00000. Review.

PMID:
21815697
8.

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.

Garçon N, Wettendorff M, Van Mechelen M.

Expert Opin Biol Ther. 2011 May;11(5):667-77. doi: 10.1517/14712598.2011.573624. Epub 2011 Apr 4. Review.

PMID:
21457083
9.
10.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
11.

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.

Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD.

PLoS One. 2008 Jan 2;3(1):e1401. doi: 10.1371/journal.pone.0001401.

12.

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators.

Vaccine. 2007 Dec 12;25(51):8585-97. Epub 2007 Oct 24.

PMID:
18031872
13.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA.

Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19.

PMID:
16828940
14.

Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.

Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ.

J Infect Dis. 2005 Dec 15;192(12):2099-107. Epub 2005 Nov 11.

PMID:
16288373
15.

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.

Vandepapelière P, Rehermann B, Koutsoukos M, Moris P, Garçon N, Wettendorff M, Leroux-Roels G.

Vaccine. 2005 Apr 8;23(20):2591-601.

PMID:
15780441
16.

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.

Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S.

Vaccine. 2002 Nov 1;20(31-32):3644-9.

PMID:
12399191
17.

Therapeutic vaccination.

Wettendorff M.

Virus Res. 2002 Jan 30;82(1-2):133-40. Review. No abstract available.

PMID:
11885940
18.

FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.

Barcy S, Wettendorff M, Leo O, Urbain J, Kruger M, Ceuppens JL, de Boer M.

Int Immunol. 1995 Feb;7(2):179-89.

PMID:
7537534
19.

Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells.

Wettendorff M, Massacrier C, Vanbervliet B, Urbain J, Banchereau J, Caux C.

Adv Exp Med Biol. 1995;378:371-4. No abstract available.

PMID:
8526096
20.

Anti-idiotype cancer vaccines: pre-clinical and clinical studies.

Herlyn D, Benden A, Kane M, Somasundaram R, Zaloudik J, Sperlagh M, Marks G, Hart E, Ralph C, Wettendorff M, et al.

In Vivo. 1991 Nov-Dec;5(6):615-23.

PMID:
1810448
21.

Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D.

Proc Natl Acad Sci U S A. 1989 May;86(10):3787-91.

22.

Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotype.

Wettendorff M, Iliopoulos D, Schmoll E, Koprowski H, Herlyn D.

J Immunol Methods. 1989 Jan 6;116(1):105-15.

PMID:
2783712
23.

Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies.

Herlyn D, Wettendorff M, Iliopoulos D, Schmoll E, Schedel I, Koprowski H.

Viral Immunol. 1989 Winter;2(4):271-6.

PMID:
2610826
24.

Modulation of cancer patients' immune responses by anti-idiotypic antibodies.

Herlyn D, Wettendorff M, Koprowski H.

Int Rev Immunol. 1989;4(4):347-57. Review.

PMID:
2519932
25.

Functional mimicry of tumor-associated antigens by antiidiotypic antibodies.

Herlyn D, Wettendorff M, Iliopoulos D, Koprowski H.

Exp Clin Immunogenet. 1988;5(4):165-75. Review.

PMID:
3078570
26.

Anti-idiotype immunization of cancer patients: modulation of the immune response.

Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, et al.

Proc Natl Acad Sci U S A. 1987 Nov;84(22):8055-9.

Supplemental Content

Loading ...
Support Center